JP6167465B2 - イミダゾ−オキサジアゾール及びイミダゾ−チアジアゾール誘導体 - Google Patents
イミダゾ−オキサジアゾール及びイミダゾ−チアジアゾール誘導体 Download PDFInfo
- Publication number
- JP6167465B2 JP6167465B2 JP2015515410A JP2015515410A JP6167465B2 JP 6167465 B2 JP6167465 B2 JP 6167465B2 JP 2015515410 A JP2015515410 A JP 2015515410A JP 2015515410 A JP2015515410 A JP 2015515410A JP 6167465 B2 JP6167465 B2 JP 6167465B2
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- halogen
- substituted
- formula
- branched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- WRFNEVMBXWQAME-UHFFFAOYSA-N Cc([nH]1)ncc1OC(c(cc1)ccc1N)=N Chemical compound Cc([nH]1)ncc1OC(c(cc1)ccc1N)=N WRFNEVMBXWQAME-UHFFFAOYSA-N 0.000 description 1
- 0 Cc1ncc2[s]c(C(N(C)*)=O)n[n]12 Chemical compound Cc1ncc2[s]c(C(N(C)*)=O)n[n]12 0.000 description 1
- ARISJAIQVOYGOD-UHFFFAOYSA-N Cc1ncc2[s]c(C(NC(C3CC3)c(cc3)ccc3Cl)=O)n[n]12 Chemical compound Cc1ncc2[s]c(C(NC(C3CC3)c(cc3)ccc3Cl)=O)n[n]12 ARISJAIQVOYGOD-UHFFFAOYSA-N 0.000 description 1
- DHLFXLKDUJTJRV-UHFFFAOYSA-N Cc1ncc2[s]c(C(NCc(cccc3)c3OCC(F)(F)F)=O)n[n]12 Chemical compound Cc1ncc2[s]c(C(NCc(cccc3)c3OCC(F)(F)F)=O)n[n]12 DHLFXLKDUJTJRV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261655544P | 2012-06-05 | 2012-06-05 | |
| US61/655,544 | 2012-06-05 | ||
| EP12170840.8 | 2012-06-05 | ||
| EP12170840.8A EP2671885A1 (en) | 2012-06-05 | 2012-06-05 | Imidazo-oxadiazole and Imidazo-thiadiazole derivatives |
| PCT/EP2013/001521 WO2013182274A1 (en) | 2012-06-05 | 2013-05-23 | Imidazo-oxadiazole and imidazo-thiadiazole derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522556A JP2015522556A (ja) | 2015-08-06 |
| JP2015522556A5 JP2015522556A5 (https=) | 2016-08-12 |
| JP6167465B2 true JP6167465B2 (ja) | 2017-07-26 |
Family
ID=46320789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015515410A Active JP6167465B2 (ja) | 2012-06-05 | 2013-05-23 | イミダゾ−オキサジアゾール及びイミダゾ−チアジアゾール誘導体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9932354B2 (https=) |
| EP (2) | EP2671885A1 (https=) |
| JP (1) | JP6167465B2 (https=) |
| CN (1) | CN104395324B (https=) |
| AU (1) | AU2013270979B2 (https=) |
| CA (1) | CA2875628C (https=) |
| ES (1) | ES2582556T3 (https=) |
| IL (1) | IL236076B (https=) |
| WO (1) | WO2013182274A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018224455A1 (en) | 2017-06-07 | 2018-12-13 | Basf Se | Substituted cyclopropyl derivatives |
| AU2018346597B2 (en) | 2017-10-06 | 2023-07-13 | Forma Therapeutics, Inc. | Inhibiting Ubiquitin Specific Peptidase 30 |
| JP7449242B2 (ja) | 2018-05-17 | 2024-03-13 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物 |
| JP7530889B2 (ja) | 2018-10-05 | 2024-08-08 | フォーマ セラピューティクス，インコーポレイテッド | ユビキチン特異的プロテアーゼ３０（ｕｓｐ３０）阻害剤として作用する縮合ピロリン |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691201A (en) * | 1993-04-26 | 1997-11-25 | Janssen Pharmaceutica, N.V. | Use of sabeluzole in chronic neurodegenerative diseases |
| ES2316546T3 (es) * | 2001-02-20 | 2009-04-16 | Astrazeneca Ab | 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3. |
| CA2450769A1 (en) * | 2001-06-15 | 2002-12-27 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidin-4-yl) benzisoxazoles as protein kinase inhibitors |
| TW200302722A (en) * | 2002-02-13 | 2003-08-16 | Astrazeneca Ab | Therapeutic agents |
| US20050154202A1 (en) * | 2002-04-05 | 2005-07-14 | Hagmann William K. | Substituted aryl amides |
| CN1319968C (zh) * | 2002-08-02 | 2007-06-06 | 沃泰克斯药物股份有限公司 | 用作gsk－3的抑制剂的吡唑组合物 |
| DK1910384T3 (da) * | 2005-08-04 | 2012-12-17 | Sirtris Pharmaceuticals Inc | Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser |
| HUE025976T2 (en) * | 2007-09-27 | 2016-05-30 | Fund Centro Nac De Investig Oncologicas Carlos Iii | Imidazolothiadiazoles for use as protein kinase inhibitors |
| AU2009275544B2 (en) * | 2008-07-29 | 2013-09-12 | Merck Patent Gmbh | Imidazothiadiazoles derivatives |
| CA2737028C (en) * | 2008-09-23 | 2017-06-27 | Wista Laboratories Ltd. | Ligands for aggregated tau molecules |
-
2012
- 2012-06-05 EP EP12170840.8A patent/EP2671885A1/en not_active Withdrawn
-
2013
- 2013-05-23 WO PCT/EP2013/001521 patent/WO2013182274A1/en not_active Ceased
- 2013-05-23 CA CA2875628A patent/CA2875628C/en active Active
- 2013-05-23 CN CN201380029418.9A patent/CN104395324B/zh active Active
- 2013-05-23 JP JP2015515410A patent/JP6167465B2/ja active Active
- 2013-05-23 US US14/402,395 patent/US9932354B2/en active Active
- 2013-05-23 ES ES13724172.5T patent/ES2582556T3/es active Active
- 2013-05-23 EP EP13724172.5A patent/EP2855488B1/en active Active
- 2013-05-23 AU AU2013270979A patent/AU2013270979B2/en active Active
-
2014
- 2014-12-04 IL IL236076A patent/IL236076B/en active IP Right Grant
-
2017
- 2017-12-01 US US15/829,030 patent/US10696690B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN104395324B (zh) | 2017-09-12 |
| EP2855488B1 (en) | 2016-04-13 |
| US20150175628A1 (en) | 2015-06-25 |
| CN104395324A (zh) | 2015-03-04 |
| EP2671885A1 (en) | 2013-12-11 |
| AU2013270979A1 (en) | 2015-01-22 |
| EP2855488A1 (en) | 2015-04-08 |
| CA2875628A1 (en) | 2013-12-12 |
| US20180215770A1 (en) | 2018-08-02 |
| AU2013270979B2 (en) | 2017-04-27 |
| US9932354B2 (en) | 2018-04-03 |
| JP2015522556A (ja) | 2015-08-06 |
| CA2875628C (en) | 2021-01-19 |
| IL236076A0 (en) | 2015-02-01 |
| IL236076B (en) | 2019-05-30 |
| WO2013182274A1 (en) | 2013-12-12 |
| ES2582556T3 (es) | 2016-09-13 |
| US10696690B2 (en) | 2020-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20080087070A (ko) | 피리미딘 또는 트리아진 융합된 비시클릭 메탈로프로테아제억제제 | |
| PT2133349E (pt) | Inibidores de cinase | |
| CA2992846A1 (en) | Novel compounds for use in cognition improvement | |
| PT2142533E (pt) | Derivados de imidazolidinona | |
| JP6229717B2 (ja) | ガンマセクレターゼモジュレーターとしての縮合トリアゾール誘導体 | |
| MXPA05004305A (es) | Compuestos de triazol para el tratamiento de dismenorrea. | |
| KR20240005892A (ko) | Lpa 수용체 길항제 및 이의 용도 | |
| IL302837A (en) | Aryl derivatives for treating trpm3 mediated disorders | |
| US10696690B2 (en) | Imidazo-oxadiazole and imidazo-thiadiazole derivatives | |
| CA2875132C (en) | Spiro tetrahydro-benzothiophen derivatives useful for the treatment of neurodegenerative diseases | |
| KR20110100624A (ko) | 다발성 경화증의 치료에 유용한 옥사디아졸 융합된 헤테로사이클릭 유도체 | |
| CA2786537A1 (fr) | Derives de 5 - oxo -5, 8- dihydropyrido [2, 3 - d] pyrimidine comme inhibiteurs de kinases camkii pour le traitement de maladies cardiovasculaires | |
| US20070072901A1 (en) | 1-Amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 | |
| TWI917479B (zh) | 用於治療ｔｒｐｍ３介導病症之芳基衍生物 | |
| KR20240093844A (ko) | Gpr39 단백질의 길항제 | |
| CN103228656A (zh) | 3-取代基-6-(吡啶基甲氧基)-吡咯并吡啶化合物 | |
| HK1161244A (en) | Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160520 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160624 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170220 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170519 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170605 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170609 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6167465 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |